

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul21zxn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Caplus
NEWS	6	May 27	Caplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	Caplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	18	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	19	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	20	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	21	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS EXPRESS			JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:53:23 ON 21 SEP 2004

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:53:35 ON 21 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2004 HIGHEST RN 748739-98-2

DICTIONARY FILE UPDATES: 20 SEP 2004 HIGHEST RN 748739-98-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\STNEXP4\QUERIES\10821698.str



chain nodes :

16 17 18 20 21 22 23 24 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Davis -10/821,698

chain bonds :

2-16 8-25 11-20 12-16 14-17 14-18 20-21 20-22 22-23 24-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 11-15 12-13 13-14
14-15

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 12-13 12-16 20-21
20-22 22-23 24-25

exact bonds :

2-16 8-25 11-15 11-20 13-14 14-15 14-17 14-18

isolated ring systems :

containing 1 : 11 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 20:CLASS


21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS

L1 STRUCTURE UPLOADED

=> dis 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 sam

SAMPLE SEARCH INITIATED 10:54:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 10:54:10 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 5 ANSWERS
 SEARCH TIME: 00.00.01

L3 5 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 10:54:19 ON 21 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2004 VOL 141 ISS 13
 FILE LAST UPDATED: 20 Sep 2004 (20040920/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 3 L3

=> s l4 and pd<july 1999

19649264 PD<JULY 1999
 (PD<19990700)


L5 0 L4 AND PD<JULY 1999

=> dis l4 1-3 bib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:521737 CAPLUS
 DN 137:78867
 TI Preparation of carboxydifluoropyrrolidinylmethyldecahydroisoquinolinecarboxylates as excitatory amino acid receptor antagonists.
 IN Khau, Vien Van; Letourneau, Michael Edward; Martinelli, Michael John
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053561	A1	20020711	WO 2001-US44715	20011220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	BR 2001016672	A	20030923	BR 2001-16672	20011220
	EP 1351955	A1	20031015	EP 2001-995980	20011220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004520335	T2	20040708	JP 2002-554680	20011220
	US 2004082606	A1	20040429	US 2003-450458	20030613
	NO 2003002973	A	20030627	NO 2003-2973	20030627
PRAI	US 2001-260014P	P	20010105		
	WO 2001-US44715	W	20011220		
OS	MARPAT 137:78867				
GI					



AB Pharmaceutically acceptable salts of title compds. (I; R1, R2 = H, alkyl, alkenyl, alkylaryl, alkylcycloalkyl, alkylidaminoalkyl, alkylpyrrolidinyl, alkylpiperidinyl, alkylmorpholinyl), were prepared A mixture of Et (3S,4aR,6S,8aR)-6-(hydroxymethyl)-2-(methoxycarbonyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate and Et3N in EtOAc is added dropwise to p-nitrobenzenesulfonyl chloride in EtOAc at 0-2° followed by warming to room temperature and stirring for 2.5 h to give 97% sulfonate ester. This was refluxed with hydroxyproline Et ester in EtOAc to give an oil, which in CH2Cl2 was added to a -10° mixture of POCl3 and Me2SO in CH2Cl2 to give 41% ketopyrrolidinylmethyldecahydrois oquinoline derivative This was stirred 21 h with deoxofluor [[bis-(2-methoxyethyl)amino]sulfur trifluoride] and EtOH in 1,2-dichloroethane to give 61% difluoropyrrolidinylmethyldecahydrois oquinoline derivative, which was N-protected with Me3SiH in CH2Cl2 followed by salification with D-mandelic acid to give Et (3S,4aR,6S,8aR)-6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoropyrrolidinyl]methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate D-(-)-mandelic acid salt. The dihydrochloride salt of the latter inhibited elec. stimulated dural protein extravasation with ID100 = 0.01 ng/kg orally in rats.

IT 317844-37-4P 440632-08-6P 440632-09-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carboxydifluoropyrrolidinylmethyldecahydroisoquinolinecarboxylates as excitatory amino acid receptor antagonists)

RN 317844-37-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoro-1-pyrrolidinyl]methyl]decahydro-, ethyl ester, dihydrochloride, (3S,4aR,6S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 440632-08-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoro-1-pyrrolidinyl]methyl]decahydro-, ethyl ester, (3S,4aR,6S,8aR)-, mono[(αR)-α-hydroxybenzeneacetate] (9CI) (CA INDEX NAME)

CM 1

CRN 317844-31-8

CMF C20 H32 F2 N2 O4

Absolute stereochemistry.




CM 2

CRN 611-71-2

CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).



RN 440632-09-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoro-1-pyrrolidinyl]methyl]decahydro-, ethyl ester, (3S,4aR,6S,8aR)-, 1,5-naphthalenedisulfonate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 317844-31-8

CMF C20 H32 F2 N2 O4


Absolute stereochemistry.



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:521727 CAPLUS

DN 137:78866

TI Preparation of pyrrolidinyl- and piperidinylmethyldecahydroisoquinolinecarboxylates as excitatory amino acid receptor antagonists.

IN Filla, Sandra Ann; Hudziak, Kevin John; Mathes, Brian Michael; Ornstein, Paul Leslie


PA Eli Lilly and Company, USA

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053555	A2	20020711	WO 2001-US44714	20011220
	WO 2002053555	A3	20030206		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1351951	A2	20031015	EP 2001-995979	20011220
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-259921P	P	20010105		
	WO 2001-US44714	W	20011220		
OS	MARPAT 137:78866				
GI					



I

AB Title compds. e.g., [I; R1 = H, Cl, Br, iodo, F, SR3, OH; R2 = H, F; R3 = (substituted) tetrazolyl, triazolyl, alkyl, carboxyalkyl; with provisos], were prepared for treatment of e.g., migraine and pain (no data). Thus, Et (3S,4aR,6S,8aR)-6-hydroxymethyl-2-methoxycarbonyldecahydroisoquinoline-3-carboxylate was tosylated followed by coupling with trans-4-OH-L-proline Et ester hydrochloride. The product was oxidized with Me2SO/(COCl)2 in CH2Cl2 followed by fluorination of the resulting ketone with DAST and deprotection with Me3SiCl to give Et (3S,4aR,6S,8aR)-6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoropyrrolidinyl]methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate.

IT 317844-31-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidinyl- and piperidinylmethyldecahydroisoquinolinecarbonylates as excitatory amino acid receptor antagonists)

RN 317844-31-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoro-1-pyrrolidinyl]methyl]decahydro-, ethyl ester, (3S,4aR,6S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:31316 CAPLUS

DN 134:91148

TI Selective iGluR5 receptor antagonists for the treatment of migraine

IN Bleakman, David; Chappell, Amy Suzon; Filla, Sandra Ann; Johnson, Kirk

Willis; Ornstein, Paul Leslie

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001001972	A2	20010111	WO 2000-US16297	20000627
	WO 2001001972	A3	20011206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000012175	A	20020305	BR 2000-12175	20000627
	TR 200200066	T2	20020422	TR 2002-200200066	20000627
	EP 1200073	A2	20020502	EP 2000-944671	20000627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003503449	T2	20030128	JP 2001-507466	20000627
	ZA 2001009747	A	20030312	ZA 2001-9747	20011127
	US 6566370	B1	20030520	US 2001-9655	20011211
	NO 2001006246	A	20020304	NO 2001-6246	20011219
	HR 2002000013	A1	20030831	HR 2002-13	20020107
	US 2003199546	A1	20031023	US 2003-383296	20030306
	US 6759418	B2	20040706		
PRAI	US 1999-142485P	P	19990706		
	US 1999-151165P	P	19990827		
	WO 2000-US16297	W	20000627		
	US 2001-9655	A1	20011211		

OS MARPAT 134:91148

AB The present invention provides a method of treating or preventing migraine which comprises administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compds. functional as selective iGluR5 receptor antagonists, i.e., isoquinoline carboxylate derivs., as well as compns.

and formulations comprising said selective iGluR5 receptor antagonists. Formulations of hard gelatin capsules, tablets, an aerosol solution, suppositories, suspensions, and i.v. injections are provided. For example, i.v. administration of 3S,4aR,6S,8aR-6-(((4-carboxy)phenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid (preparation given) inhibited dural protein extravasation, a functional characteristic of migraine, with ID50 of 6.5 and 4.0 ng/kg in rats and guinea pigs, resp.


IT 317844-31-8P 317844-35-2P 317844-37-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of selective iGluR receptor antagonists for treatment of migraine)

RN 317844-31-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoro-1-pyrrolidinyl]methyl]decahydro-, ethyl ester, (3S,4aR,6S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 317844-35-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoro-1-pyrrolidinyl]methyl]decahydro-, ethyl ester, (3S,4aR,6S,8aR)-, mono(α -hydroxybenzeneacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 317844-31-8

CMF C20 H32 F2 N2 O4


Absolute stereochemistry.



CM 2

CRN 90-64-2


CMF C8 H8 O3



RN 317844-37-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-[[[(2S)-2-(ethoxycarbonyl)-4,4-difluoro-1-pyrrolidinyl]methyl]decahydro-, ethyl ester, dihydrochloride,
(3S,4aR,6S,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.98

172.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.10

-2.10

STN INTERNATIONAL LOGOFF AT 10:55:19 ON 21 SEP 2004